AN2 Therapeutics, Inc. Operating Cash Flow
AN2 Therapeutics, Inc. (ANTX) reported Operating Cash Flow of -$19.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- AN2 Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$7.00M.
- AN2 Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$12.07M.
- AN2 Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$5.24M.
- AN2 Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$6.38M.
- AN2 Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$29.83M.
- AN2 Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$49.26M.
- AN2 Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$53.29M.
- AN2 Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$33.46M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$19.07M 10-Q · filed 2026-08-11 | -$24.31M derived: sum of 3 quarters · filed 2026-08-11 | -$30.68M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$12.07M 10-Q · filed 2026-05-11 | -$17.31M derived: sum of 2 quarters · filed 2026-05-11 | -$23.68M derived: sum of 3 quarters · filed 2026-05-11 | -$31.28M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$5.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$11.61M derived: sum of 2 quarters · filed 2026-03-17 | -$19.21M derived: sum of 3 quarters · filed 2026-08-11 | -$29.83M 10-K · filed 2026-03-17 |
| 2025-09-30 | -$6.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$13.97M derived: sum of 2 quarters · filed 2026-08-11 | -$24.60M 10-Q · filed 2025-11-12 | -$29.87M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$7.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$18.22M 10-Q · filed 2026-08-11 | -$23.50M derived: sum of 3 quarters · filed 2026-08-11 | -$35.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$10.62M 10-Q · filed 2026-05-11 | -$15.90M derived: sum of 2 quarters · filed 2026-05-11 | -$27.90M derived: sum of 3 quarters · filed 2026-05-11 | -$42.29M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$5.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$17.28M derived: sum of 2 quarters · filed 2026-03-17 | -$31.66M derived: sum of 3 quarters · filed 2026-03-17 | -$49.26M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$12.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$26.39M derived: sum of 2 quarters · filed 2025-11-12 | -$43.98M 10-Q · filed 2025-11-12 | -$61.05M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$14.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$31.98M 10-Q · filed 2025-08-12 | -$49.05M derived: sum of 3 quarters · filed 2025-08-12 | -$60.84M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$17.59M 10-Q · filed 2025-05-13 | -$34.66M derived: sum of 2 quarters · filed 2025-05-13 | -$46.46M derived: sum of 3 quarters · filed 2025-05-13 | -$59.28M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$17.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$28.87M derived: sum of 2 quarters · filed 2025-03-25 | -$41.69M derived: sum of 3 quarters · filed 2025-03-25 | -$53.29M 10-K · filed 2025-03-25 |
| 2023-09-30 | -$11.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$24.62M derived: sum of 2 quarters · filed 2024-11-13 | -$36.22M 10-Q · filed 2024-11-13 | -$43.86M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$12.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$24.42M 10-Q · filed 2024-08-13 | -$32.06M derived: sum of 3 quarters · filed 2024-08-13 | -$41.55M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$11.60M 10-Q · filed 2024-05-14 | -$19.23M derived: sum of 2 quarters · filed 2024-05-14 | -$28.72M derived: sum of 3 quarters · filed 2024-05-14 | -$38.32M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$7.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$17.13M derived: sum of 2 quarters · filed 2024-03-29 | -$26.72M derived: sum of 3 quarters · filed 2024-03-29 | -$33.46M 10-K · filed 2024-03-29 |
| 2022-09-30 | -$9.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$19.08M derived: sum of 2 quarters · filed 2023-11-09 | -$25.82M 10-Q · filed 2023-11-09 | -$34.82M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$9.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$16.34M 10-Q · filed 2023-08-10 | -$25.33M derived: sum of 3 quarters · filed 2023-08-10 | -$30.02M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$6.74M 10-Q · filed 2023-05-11 | -$15.73M derived: sum of 2 quarters · filed 2023-05-11 | -$20.43M derived: sum of 3 quarters · filed 2023-05-11 | -$25.68M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$8.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$13.68M derived: sum of 2 quarters · filed 2023-03-29 | -$18.94M derived: sum of 3 quarters · filed 2023-03-29 | -$20.48M 10-K · filed 2023-03-29 |
| 2021-09-30 | -$4.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$9.95M derived: sum of 2 quarters · filed 2022-11-09 | -$11.49M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | -$5.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$6.80M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$1.54M 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |